 Seagen Inc NASDAQ: SGEN and Astellas Pharma Inc OTC: ALPMF announced the initial results from Cohort H of the EV-103 trial investigating PADCEV enfortumab vedotin-ejfv in muscle-invasive bladder cancer MIBC who are ineligible for cisplatin-based chemotherapy. Data will be presented at the 2022 ASCO Genitourinary Cancers Symposium ASCO GU. 